FinVector regulatory team is fully versant in the standards that are required for Gene Therapy and Viral Vectors.

FinVector has written CMC (Quality) sections for clinical trials of its own products and Market Authorisation Applications, and can provide assistance to the client.

As FinVector has worked on Gene Therapy products that have undergone late stage phase III clinical trial as well as early stage clinical trials, FinVector can bring this direct knowledge to assist you in your  CMC submission and all stages of regulatory submissions.